Survival, clinical, and genetic findings in paediatric cardiomyopathy: a five-year prospective study from Brazil

Ana Flávia M Torbey1,2, Raquel G T Couto3, Aurea Lucia A A G de Souza1,3

  • 1Fluminense Federal University, Niterói, Rio de Janeiro, Brazil.

Cardiology in the Young
|September 25, 2025
PubMed

Insights

This study reveals high genetic positivity in Brazilian pediatric cardiomyopathy patients, especially with systemic involvement. Key clinical factors predict mortality, aiding risk stratification and care for these complex heart conditions.

Area of Science:

  • Cardiology
  • Genetics
  • Pediatrics

Background:

  • Limited prospective cohort studies exist on pediatric cardiomyopathies in Brazil, particularly integrating clinical and genetic data.
  • This study addresses the gap by examining a cohort in a Brazilian metropolitan region.

Purpose of the Study:

  • To characterize the clinical and genetic profiles of pediatric cardiomyopathy patients in Brazil.
  • To identify predictors of mortality in this population to improve patient management.

Main Methods:

  • A prospective observational study was conducted on pediatric patients diagnosed with cardiomyopathies.
  • Clinical data, genetic findings, and survival outcomes were collected and analyzed.
  • Kaplan-Meier curves were used to assess survival rates and identify significant predictors.

Main Results:

  • The study included 45 pediatric patients, with a male predominance and a mean age of 6.5 years at diagnosis. Dilated and hypertrophic cardiomyopathies were most prevalent.
  • Genetic testing revealed a 60% positivity rate, significantly higher in cases with multi-organ/system involvement (77.7%).
  • Mortality was 11.1%, with significantly lower survival associated with reduced ejection fraction (<30%), advanced functional class (III/IV), heart failure, extensive medication use, elevated NT-proBNP (>1000 pg/mL), and heart transplant indication.

Conclusions:

  • This research provides crucial new data on pediatric cardiomyopathies in Brazil, emphasizing a high rate of genetic diagnoses.
  • The findings underscore the importance of genetic testing, especially in patients with systemic manifestations.
  • Identified clinical predictors of mortality are vital for refining risk stratification and guiding clinical care strategies.
Abstract

Related Concept Videos

Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...